Transce3nd’s Idexx Laboratories IDXX Stock Holding History

Transce3nd’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$413	–	1370
2024 Q4	$413	Buy	+1	New	+$439	﹤0.01%	1329

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Transce3nd's IDXX Position: Q1 2025 in Review

Transce3nd sold out of Idexx Laboratories (IDXX) in Q1 2025, closing a stake of 1 share — an estimated $413 sold.

Transce3nd first reported a position in IDXX in Q4 2024 and held it in 1 quarter. The position peaked at $413 in Q4 2024. 1,142 funds tracked by Wall St. Rank hold IDXX as of Q1 2025.

Transce3nd reported no remaining Idexx Laboratories position as of Q1 2025 after selling out during the quarter.
Transce3nd sold 1 Idexx Laboratories share in Q1 2025, an estimated $413.
Transce3nd first reported a position in Idexx Laboratories in Q4 2024 and held it in 1 quarter.
Transce3nd's Idexx Laboratories position peaked at $413 in Q4 2024.
1,142 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.